Pharmaceutical compositions comprising proton pump inhibitors and gastrin/cholecystokinin receptor ligands
First Claim
1. A pharmaceutical composition comprising a proton pump inhibitor and a compound of the formula (I)
2 Assignments
0 Petitions
Accused Products
Abstract
Pharmaceutical compositions comprising a proton pump inhibitor and a compound of the formula (I) or its pharmaceutically acceptable salts, are useful in treating gastrointestinal disorders. X and Y are independently ═N—, —N(R5)— (R5 being selected from H, Me, Et, Pr, Bn, —OH and —CH2COOR6, wherein R6 represents H, Me, Et, Pr or Bn), ═CH—, S— or —O—; n is from 1 to 4; R1 is H or C1 to C15 hydrocarbyl wherein up to three C atoms may optionally be replaced by N, O and/or S atoms and up to three H atoms may optionally be replaced by halogen atoms; R2 is selected from H, Me, Et, Pr and OH, each R2 being independently selected from H, Me, Et, Pr and OH when n is greater than 1; R3 (when n is 1) is selected from H, Me, Et and Pr; or (when n is greater than 1) each R3 is independently selected from H, Me, Et, and Pr, or two R3 groups on neighbouring carbon atoms which are linked by a double bond; or R2 and R3 on the same carbon atom are linked to form a C3 to C6 carbocylic ring, or two R3 groups are absent from neighbouring carbon atoms which are linked by a double bond; or R2 and R3 on the same carbon atom together represent an ═O group; R4 is C1 to C15 hydrocarbyl wherein up to two C atoms may optionally be replaced by N, O and/or S atoms and up to two H atoms may optionally be replaced by halogen atoms; Z is —(NR7)a—CO—(NR8)b— (wherein a is 0 or 1, b is 0 or 1, and R7 and R8 are independently selected from the groups recited above for R6), —CO—NR7—CH2—CO—NR8—, —CO—O—, —CH2—CH2—, —CH═CH—, —CH2—NR— or a bond; Q is —R9V, or (II) (wherein R9 is —CH2—; —CH2—CH2—; or (III) R9 and R8, together with the nitrogen atom to which R8 is attached, form a piperidine or pyrrolidine ring which is substitued by V; V is —CO—NH—SO2-Ph, SO2—NH—CO-Ph, —CH2OH, or a group of the formula —R10U, (wherein U is —COOH, tetrazolyl, —CONHOH— or —SO3H; and R10 is a bond; C1 to C6 hydrocarbylene, optionally substituted by hydroxy, amino or acetamido; —O—(C1 to C3 alkylene)-; —SO2NR11—CHR12—; —CO—NR11—CHR12—, R11 and R12 being independently selected from H and methyl; or —NH—(CO), —CH2—, c being 0 or 1); T is C1 to C6 hydrocarbyl, —NR6R7 (wherein R6 and R7 are as defined above), —OMe, —OH, —CH2OH, halogen or trihalomethyl; m is 1 or 2; p is from 0 to 3; and q is from 0 to 2, with the proviso that q is 1 or 2 when Z is a bond).
-
Citations
35 Claims
- 1. A pharmaceutical composition comprising a proton pump inhibitor and a compound of the formula (I)
-
27. A product containing as first active ingredient a compound of formula (I) and as second active ingredient a proton pump inhibitor, as a combined preparation for simultaneous, separate or sequential use in the treatment of patients suffering from gastrointestinal disorders.
-
29. Use of a proton pump inhibitor for the preparation of a medicament for the treatment of gastrointestinal disorders, said treatment comprising the simultaneous or sequential administration of said proton pump inhibitor and a compound of formula (I), wherein said proton pump inhibitor enhances the effect of the compound of formula (I) on gastrin-related disorders in patients suffering from gastrointestinal disorders.
-
30. Use of a compound of formula (I) for the preparation of a medicament for the treatment of gastrointestinal disorders, said treatment comprising the simultaneous or sequential administration of said proton pump inhibitor and a compound of formula (I), wherein said compound of formula (I) enhances the effect of the proton pump inhibitor on the reduction of acid secretion in patients suffering from gastrointestinal disorders.
- 31. Use of a compound of formula (I) for the preparation of a medicament for reducing adverse effects associated with administration of proton pump inhibitors in patients suffering from gastrointestinal disorders.
-
33. Use of a proton pump inhibitor for the preparation of a medicament for reducing adverse effects associated with administration of a compound of formula (I) in patients suffering from gastrointestinal disorders.
Specification